ReviR Therapeutics has signed a research collaboration and option-to-license agreement with Asieris Pharmaceuticals to discover new oncology therapeutics.
The collaboration is aimed at discovering and developing new advanced treatments for genitourinary (GU) tumours as well as other related serious diseases using ReviR’s RNA-targeted technologies.
Under the agreement, Asieris will use the advanced RNA modulation technologies, BindeR and SpliceR, of ReviR for identifying and developing new therapies that target RNA for cancer treatment.
ReviR combines computational and high throughput drug discovery technologies to deliver advanced medicines to patients.
The company’s VoyageR AI platform integrates computational methods to drug traditionally undruggable RNA targets.
Its initial focus is to develop therapeutics in oncology, CNS, and genetically defined disease indications.
Asieris Pharmaceuticals discovers, develops, and markets advanced therapeutics to treat GU tumours and other related diseases.
ReviR Therapeutics chief scientific officer Paul August said: “Asieris is a global biopharma company specialised in the development of GU oncology therapies, and we are excited to be working with them to discover new treatments for indications of interests.
“Our BindeR and SpliceR platform technologies have the potential to advance therapeutics for undruggable cancer targets, and we believe this collaboration will accelerate the discovery of new treatments for patients.”
The company is focused on developing RNA-targeting small molecule therapies to treat cancer and other serious genetically defined diseases.
It uses technologies to develop therapeutics that modulate the target RNA, to develop disease-modifying treatments.
Asieris Translational Research head and Discovery Biology vice president Alice Chen said: “We are pleased to be collaborating with ReviR, an innovative biopharmaceutical company focused on the development of RNA-targeting small molecule therapies.
“We believe that our in-house R&D expertise on small molecule oncology drug discovery, combined with ReviR’s proprietary RNA-targeted technologies, will speed the benefit to patients.
“We will continue to adhere to our differentiated R&D strategy, focus on genitourinary tumours and related diseases, and expand the global reach of our innovation to deliver novel drug products for patients in China and globally.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
